KPTI News and Press, Karyopharm Therapeutics Inc. From 05/20/22

Karyopharm Therapeutics (NASDAQ:KPTI) on Friday said a European Union drug regulator committee had recommended extending the indication for the company's medicine Nexpovio for the treatment of patients with multiple myeloma, a type of white blood cell cancer. KPTI stock +4.6% t...

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma PR Newswire ̶  European Commission Decision Anticipated within Approximately 60 Days – ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress PR Newswire NEWTON, Mass. , May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmac...

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q1 2022 Earnings Call May 05, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q1 2022 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (KPTI) Q1 2022 Earnings Conference Call May 05, 2022, 08:30 ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - ...

KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data

Karyopharm Therapeutics press release (NASDAQ:KPTI): Q1 GAAP EPS of -$0.53 beats by $0.14. Revenue of $47.67M (+104.9% Y/Y) beats by $13.26M. Based on its current operating plans, Karyopharm reaffirms the following for full year 2022: XPOVIO net product revenue to be in the range of $135 mill...

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved First Quarter 2022 Net Revenues of $47.7 Million , Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from ...